Pharming Group (PHAR) Stock Price, News & Analysis

Company Overview

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe. RUCONEST represents the first recombinant C1 inhibitor therapy, offering an alternative to plasma-derived treatments and addressing key safety and supply concerns associated with conventional sources. Pharming continues to support RUCONEST through lifecycle management initiatives and expanded patient access programs.

Beyond its marketed product, Pharming’s research and development pipeline includes additional indications for C1 esterase inhibitor in prophylactic HAE treatment and novel programs targeting other rare and genetic disorders. Preclinical efforts leverage the same transgenic expression platform to explore therapies for conditions such as alpha-1 antitrypsin deficiency and metabolic disorders. Strategic collaborations and licensing agreements underpin the company’s approach to expanding its portfolio and reaching underserved patient populations.

Pharming Group serves patients and partners across Europe, North America, Latin America and Asia-Pacific through a combination of direct commercial operations and regional partnerships. The company is led by Chief Executive Officer Sijmen de Vries, whose experience in biotechnology and global product commercialization supports Pharming’s mission to deliver life-transforming therapies to individuals affected by rare diseases.

Key Stats

• Today's Range: $11.45 to $12.21
• 50-Day Range: $9.82 to $14.41
• 52-Week Range: $9.62 to $21.34
• Volume: 23,168 shs
• Average Volume: 19,227 shs
• Market Capitalization: $811.14 million
• P/E Ratio: 95.50
• Dividend Yield: N/A
• Price Target: $38.67
• Consensus Rating: Hold

Pharming Group Stock Analysis - MarketRank™

Pharming Group scored higher than 74% of companies evaluated by MarketBeat, and ranked 166th out of 917 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Hold

Consensus Rating

Pharming Group has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 2 sell ratings.

Upside Potential

Pharming Group has a consensus price target of $38.67, representing about 237.4% upside from its current price of $11.46.

Amount of Analyst Coverage

Pharming Group has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 20.00%

Earnings Growth

Earnings for Pharming Group are expected to grow by 20.00% in the coming year, from $0.25 to $0.30 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Pharming Group is 95.50, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 39.61.

Price to Earnings Ratio vs. Sector

The P/E ratio of Pharming Group is 95.50, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 271.38.

Price to Book Value per Share Ratio

Pharming Group has a P/B Ratio of 2.90. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.03% of the float of Pharming Group has been sold short.

Short Interest Ratio / Days to Cover

Pharming Group has a short interest ratio ("days to cover") of 1.98, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Pharming Group has recently increased by 92.99%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Pharming Group does not currently pay a dividend.

Dividend Growth

Pharming Group does not have a long track record of dividend growth.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Pharming Group insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.07% of the stock of Pharming Group is held by insiders.

Percentage Held by Institutions

0.03% of the stock of Pharming Group is held by institutions.

Company Calendar

• Last Earnings: 7/30/2026
• Today: 8/24/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:PHAR
• CIK: 1828316
• Web: www.pharming.com
• Phone: 31-71-524-7400
• Fax: N/A
• Employees: 280
• Year Founded: 1988

Price Target and Rating

• Average Price Target for Pharming Group: $38.67
• High Price Target: $41.00
• Low Price Target: $37.00
• Potential Upside/Downside: +237.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.20
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.12
• Trailing P/E Ratio: 95.50
• Forward P/E Ratio: 45.84
• P/E Growth: N/A
• Net Income: $2.85 million
• Net Margins: 2.51%
• Pretax Margin: 4.31%
• Return on Equity: 3.40%
• Return on Assets: 1.90%

Debt

• Debt-to-Equity Ratio: 0.34
• Current Ratio: 3.01
• Quick Ratio: 2.31

Sales & Book Value

• Annual Sales: $376.13 million
• Price / Sales: 2.16
• Cash Flow: $0.19 per share
• Price / Cash Flow: 59.09
• Book Value: $3.95 per share
• Price / Book: 2.90

Miscellaneous

• Outstanding Shares: 70,780,000
• Free Float: 69,313,000
• Market Cap: $811.14 million
• Optionable: Not Optionable
• Beta: -0.01